Infliximab partially alleviates the bite force reduction in a mouse model of temporomandibular joint pain.
Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea. ; Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea.
Sang-Hyon
0000-0002-8030-7939
SH
Kim
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Chang-Nam
0000-0002-1722-2190
CN
Son
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Hyo-Jung
0000-0003-3126-0086
HJ
Lee
Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Ho-Chan
0000-0002-3727-000X
HC
Cho
Pain Research Center, School of Medicine, Keimyung University, Daegu, Korea. ; Department of Psychiatry, Keimyung University Dongsan Medical Center, Daegu, Korea.
Sung-Won
0000-0002-2300-742X
SW
Jung
Department of Internal Medicine, School of Medicine, Yeungnam University, Daegu, Korea.
Ji An
0000-0003-3219-8368
JA
Hur
Department of Microbiology, School of Medicine, Keimyung University, Daegu, Korea.
Won-Ki
0000-0001-9123-4096
WK
Baek
Department of Pathology, Keimyung University Dongsan Medical Center, Daegu, Korea.
Hye Ra
0000-0002-1477-6606
HR
Jung
Department of Anesthesiology and Pain Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Ji Hee
0000-0003-3292-3822
JH
Hong
D000818:Animals; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001732:Bite Force; D004195:Disease Models, Animal; D005620:Freund's Adjuvant / Q000633:toxicity; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D013704:Temporomandibular Joint / Q000473:pathology; D013705:Temporomandibular Joint Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
D018501:Antirheumatic Agents; D005620:Freund's Adjuvant; D000069285:Infliximab
Bite Force; Infliximab; Temporomandibular Joint Pain